166 related articles for article (PubMed ID: 29061759)
1.
Leechawengwongs M; Prammananan T; Jaitrong S; Billamas P; Makhao N; Thamnongdee N; Thanormchat A; Phurattanakornkul A; Rattanarangsee S; Ratanajaraya C; Disratthakit A; Chaiprasert A
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29061759
[TBL] [Abstract][Full Text] [Related]
2. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Disratthakit A; Prammananan T; Tribuddharat C; Thaipisuttikul I; Doi N; Leechawengwongs M; Chaiprasert A
Antimicrob Agents Chemother; 2016 Sep; 60(9):5189-97. PubMed ID: 27297489
[TBL] [Abstract][Full Text] [Related]
3. Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran.
Sayadi M; Zare H; Jamedar SA; Hashemy SI; Meshkat Z; Soleimanpour S; Hoffner S; Ghazvini K
BMC Infect Dis; 2020 Jun; 20(1):390. PubMed ID: 32487030
[TBL] [Abstract][Full Text] [Related]
4. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
[TBL] [Abstract][Full Text] [Related]
5. Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center.
Chand AB; Basnet A; Maharjan B; Rai G; Joshi YP; Bhatt LR; Sen B; Rai SK
PLoS One; 2024; 19(5):e0301210. PubMed ID: 38709710
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.
Niward K; Ängeby K; Chryssanthou E; Paues J; Bruchfeld J; Jureen P; Giske CG; Kahlmeter G; Schön T
J Antimicrob Chemother; 2016 Feb; 71(2):333-8. PubMed ID: 26538509
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China.
Zhu C; Zhang Y; Shen Y; Siu GK; Wu W; Qian X; Deng G; Xu Y; Lau R; Fan X; Zhang W; Lu H; Yam WC
Diagn Microbiol Infect Dis; 2012 Jul; 73(3):260-3. PubMed ID: 22560167
[TBL] [Abstract][Full Text] [Related]
8. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing.
Chen J; Peng P; Du Y; Ren Y; Chen L; Rao Y; Wang W
BMC Infect Dis; 2017 Apr; 17(1):300. PubMed ID: 28438132
[TBL] [Abstract][Full Text] [Related]
9.
Pang Y; Zong Z; Huo F; Jing W; Ma Y; Dong L; Li Y; Zhao L; Fu Y; Huang H
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739779
[TBL] [Abstract][Full Text] [Related]
10. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
11. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
Chaoui I; Oudghiri A; El Mzibri M
J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin.
Singh P; Jain A; Dixit P; Prakash S; Jaiswal I; Venkatesh V; Singh M
J Antibiot (Tokyo); 2015 Jan; 68(1):63-6. PubMed ID: 25052485
[TBL] [Abstract][Full Text] [Related]
13. Comparison of
Zong Z; Jing W; Shi J; Wen S; Zhang T; Huo F; Shang Y; Liang Q; Huang H; Pang Y
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844043
[TBL] [Abstract][Full Text] [Related]
14. Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates.
Bakuła Z; Napiórkowska A; Kamiński M; Augustynowicz-Kopeć E; Zwolska Z; Bielecki J; Jagielski T
J Microbiol Immunol Infect; 2016 Jun; 49(3):439-44. PubMed ID: 26117528
[TBL] [Abstract][Full Text] [Related]
15. Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.
Singhal R; Reynolds PR; Marola JL; Epperson LE; Arora J; Sarin R; Myneedu VP; Strong M; Salfinger M
J Clin Microbiol; 2016 Sep; 54(9):2298-305. PubMed ID: 27335153
[TBL] [Abstract][Full Text] [Related]
16. Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients.
Kabir S; Tahir Z; Mukhtar N; Sohail M; Saqalein M; Rehman A
BMC Pulm Med; 2020 May; 20(1):138. PubMed ID: 32393213
[TBL] [Abstract][Full Text] [Related]
17. Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil.
Matsui T; Pinhata JMW; Rabello MCDS; Brandão AP; Ferrazoli L; Leão SC; Viana-Niero C; Oliveira RS
Mem Inst Oswaldo Cruz; 2020; 115():e200055. PubMed ID: 32401997
[TBL] [Abstract][Full Text] [Related]
18. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016).
Kateete DP; Kamulegeya R; Kigozi E; Katabazi FA; Lukoye D; Sebit SI; Abdi H; Arube P; Kasule GW; Musisi K; Dlamini MG; Khumalo D; Joloba ML
BMC Pulm Med; 2019 Jul; 19(1):124. PubMed ID: 31291943
[TBL] [Abstract][Full Text] [Related]
19. Second-line drug susceptibilities of multidrug-resistant tuberculosis strains isolated in Thailand: an update.
Chaiprasert A; Srimuang S; Tingtoy N; Makhao N; Sirirudeeporn P; Tomnongdee N; Theankeaw O; Charoensook S; Leechawengwongs M; Prammananan T
Int J Tuberc Lung Dis; 2014 Aug; 18(8):961-3. PubMed ID: 25199012
[TBL] [Abstract][Full Text] [Related]
20. Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance.
Ei PW; Aung WW; Nyunt WW; Swe TL; Htwe MM; Win SM; Aung ST; Chang CL; Lee HY; Lee JS
Int J Tuberc Lung Dis; 2018 Jan; 22(1):47-53. PubMed ID: 29297425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
